Share Price and Basic Stock Data
Last Updated: January 1, 2026, 12:45 pm
| PEG Ratio | 6.55 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bal Pharma Ltd operates in the pharmaceuticals sector and reported a market capitalization of ₹116 Cr. The company’s stock price stood at ₹72.6, reflecting a Price-to-Earnings (P/E) ratio of 17.0, which indicates a moderate valuation compared to industry peers. Revenue from operations has shown a positive trajectory, with sales increasing from ₹281 Cr in FY 2022 to ₹304 Cr in FY 2023, and further to ₹339 Cr in FY 2024. The quarterly sales figures also highlight this growth, with a notable rise to ₹94.63 Cr in Mar 2024, although it slightly declined to ₹81.88 Cr in Mar 2025. The trailing twelve months (TTM) revenue was reported at ₹295 Cr, demonstrating a resilient performance despite fluctuations in specific quarters. The company’s operational management can be seen in its ability to generate consistent sales, albeit with challenges in maintaining quarter-on-quarter growth.
Profitability and Efficiency Metrics
Bal Pharma’s profitability metrics reflect a mixed performance in recent periods. The Operating Profit Margin (OPM) for FY 2024 was reported at 9.20%, slightly improving to 10.14% in Mar 2024, indicating better operational efficiency. The net profit for the same fiscal year stood at ₹7 Cr, translating to an Earnings Per Share (EPS) of ₹4.54. However, the net profit margin has fluctuated, with a recorded margin of 2.38% in Mar 2025, which is modest compared to industry standards. The company’s Return on Equity (ROE) was reported at 9.66%, while the Return on Capital Employed (ROCE) stood at 10.1%, suggesting that the company is generating reasonable returns on its equity base. The interest coverage ratio (ICR) of 1.88x indicates that Bal Pharma can comfortably meet its interest obligations, though a lower ratio compared to sector norms might raise concerns about financial flexibility.
Balance Sheet Strength and Financial Ratios
Bal Pharma’s balance sheet reveals a total asset base of ₹336 Cr and total borrowings of ₹155 Cr, leading to a debt-to-equity ratio of 1.94x, which is relatively high and could pose risks in a rising interest rate environment. The company reported reserves of ₹62 Cr, which adds a layer of financial stability. The liquidity position, as reflected by the current ratio of 1.07x, indicates a reasonably sound ability to cover short-term liabilities, although it is slightly below the ideal threshold. Inventory turnover has improved to 3.18x in Mar 2025, suggesting better management of inventory levels. The price-to-book value ratio stood at 1.71x, indicating that the stock is trading at a premium over its book value, which may attract investor interest but also raises questions about valuation sustainability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Bal Pharma indicates a stable ownership structure, with promoters holding 50.87% of the shares, reflecting strong insider confidence in the company’s future. The foreign institutional investors (FIIs) have a minimal stake of 0.23%, suggesting limited interest from international investors. The public holds 48.91%, which indicates a broad base of retail investors. The number of shareholders decreased from 16,466 in Dec 2022 to 15,774 by Sep 2025. This decline may raise concerns about investor sentiment, particularly if it reflects dissatisfaction with the stock’s performance. However, the stable promoter holding provides a cushion against volatility, which may reassure existing investors. The dividend payout ratio of 26.47% in Mar 2025 highlights a commitment to returning value to shareholders, although the payout has been inconsistent in previous years.
Outlook, Risks, and Final Insight
Looking ahead, Bal Pharma faces both opportunities and challenges. The company’s ability to sustain revenue growth amidst fluctuating quarterly performance will be crucial. Risks include high leverage indicated by a debt-to-equity ratio of 1.94x, which could impact financial stability in adverse market conditions. Moreover, the slight decline in public shareholding may indicate waning investor confidence, which Bal Pharma must address. The company has strengths in its operational profitability metrics and a solid reserve base, which can support future growth initiatives. To enhance its market position, Bal Pharma could focus on improving its debt management strategies and increasing its engagement with institutional investors to broaden its shareholder base. The ability to navigate these dynamics will determine its future trajectory in the competitive pharmaceuticals landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 129 Cr. | 103 | 231/84.3 | 28.6 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,816 Cr. | 442 | 479/192 | 99.7 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.5 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 52.4 Cr. | 35.8 | 36.4/17.0 | 125 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,150.20 Cr | 1,152.36 | 53.49 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 69.84 | 75.31 | 76.62 | 82.45 | 70.39 | 92.54 | 81.66 | 94.63 | 74.36 | 73.69 | 73.15 | 81.88 | 65.87 |
| Expenses | 64.80 | 69.53 | 70.47 | 74.29 | 63.95 | 84.84 | 73.87 | 85.03 | 67.89 | 66.00 | 65.40 | 74.24 | 59.81 |
| Operating Profit | 5.04 | 5.78 | 6.15 | 8.16 | 6.44 | 7.70 | 7.79 | 9.60 | 6.47 | 7.69 | 7.75 | 7.64 | 6.06 |
| OPM % | 7.22% | 7.67% | 8.03% | 9.90% | 9.15% | 8.32% | 9.54% | 10.14% | 8.70% | 10.44% | 10.59% | 9.33% | 9.20% |
| Other Income | 0.24 | 0.05 | 0.46 | 0.19 | 0.16 | 0.14 | 0.10 | 2.45 | 0.82 | -0.20 | 0.51 | 1.08 | 0.72 |
| Interest | 2.37 | 2.86 | 3.11 | 3.85 | 3.64 | 3.82 | 3.66 | 4.14 | 4.24 | 3.65 | 5.01 | 3.95 | 4.05 |
| Depreciation | 2.23 | 2.37 | 2.45 | 2.09 | 2.53 | 2.42 | 2.96 | 2.16 | 2.43 | 2.48 | 2.69 | 2.18 | 2.52 |
| Profit before tax | 0.68 | 0.60 | 1.05 | 2.41 | 0.43 | 1.60 | 1.27 | 5.75 | 0.62 | 1.36 | 0.56 | 2.59 | 0.21 |
| Tax % | 58.82% | 78.33% | 43.81% | 32.78% | 79.07% | 39.38% | 33.07% | 3.65% | 58.06% | 23.53% | 7.14% | -108.88% | 0.00% |
| Net Profit | 0.28 | 0.12 | 0.59 | 1.62 | 0.09 | 0.97 | 0.85 | 5.53 | 0.26 | 1.04 | 0.52 | 5.41 | 0.21 |
| EPS in Rs | 0.18 | 0.07 | 0.36 | 1.02 | 0.05 | 0.61 | 0.56 | 3.46 | 0.16 | 0.65 | 0.30 | 3.41 | 0.13 |
Last Updated: August 20, 2025, 1:10 pm
Below is a detailed analysis of the quarterly data for Bal Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 65.87 Cr.. The value appears to be declining and may need further review. It has decreased from 81.88 Cr. (Mar 2025) to 65.87 Cr., marking a decrease of 16.01 Cr..
- For Expenses, as of Jun 2025, the value is 59.81 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 74.24 Cr. (Mar 2025) to 59.81 Cr., marking a decrease of 14.43 Cr..
- For Operating Profit, as of Jun 2025, the value is 6.06 Cr.. The value appears to be declining and may need further review. It has decreased from 7.64 Cr. (Mar 2025) to 6.06 Cr., marking a decrease of 1.58 Cr..
- For OPM %, as of Jun 2025, the value is 9.20%. The value appears to be declining and may need further review. It has decreased from 9.33% (Mar 2025) to 9.20%, marking a decrease of 0.13%.
- For Other Income, as of Jun 2025, the value is 0.72 Cr.. The value appears to be declining and may need further review. It has decreased from 1.08 Cr. (Mar 2025) to 0.72 Cr., marking a decrease of 0.36 Cr..
- For Interest, as of Jun 2025, the value is 4.05 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.95 Cr. (Mar 2025) to 4.05 Cr., marking an increase of 0.10 Cr..
- For Depreciation, as of Jun 2025, the value is 2.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.18 Cr. (Mar 2025) to 2.52 Cr., marking an increase of 0.34 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.21 Cr.. The value appears to be declining and may need further review. It has decreased from 2.59 Cr. (Mar 2025) to 0.21 Cr., marking a decrease of 2.38 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be increasing, which may not be favorable. It has increased from -108.88% (Mar 2025) to 0.00%, marking an increase of 108.88%.
- For Net Profit, as of Jun 2025, the value is 0.21 Cr.. The value appears to be declining and may need further review. It has decreased from 5.41 Cr. (Mar 2025) to 0.21 Cr., marking a decrease of 5.20 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.13. The value appears to be declining and may need further review. It has decreased from 3.41 (Mar 2025) to 0.13, marking a decrease of 3.28.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:35 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 179 | 187 | 198 | 229 | 211 | 225 | 171 | 251 | 281 | 304 | 339 | 303 | 295 |
| Expenses | 161 | 170 | 183 | 214 | 194 | 207 | 166 | 226 | 257 | 279 | 308 | 273 | 268 |
| Operating Profit | 18 | 17 | 15 | 15 | 17 | 18 | 5 | 25 | 24 | 25 | 31 | 30 | 27 |
| OPM % | 10% | 9% | 7% | 6% | 8% | 8% | 3% | 10% | 9% | 8% | 9% | 10% | 9% |
| Other Income | 1 | 1 | 1 | 3 | 2 | 1 | 2 | 1 | 5 | 1 | 3 | 2 | 3 |
| Interest | 7 | 7 | 6 | 8 | 9 | 13 | 13 | 12 | 11 | 12 | 15 | 17 | 17 |
| Depreciation | 5 | 7 | 7 | 6 | 7 | 6 | 8 | 10 | 9 | 9 | 10 | 10 | 10 |
| Profit before tax | 7 | 5 | 3 | 3 | 3 | -0 | -14 | 4 | 9 | 5 | 9 | 5 | 4 |
| Tax % | 23% | 25% | 90% | 114% | 87% | -1,175% | -5% | -15% | 38% | 45% | 18% | -41% | |
| Net Profit | 5 | 4 | 1 | -0 | 0 | 2 | -13 | 5 | 6 | 3 | 7 | 7 | 7 |
| EPS in Rs | 4.56 | 2.82 | 1.10 | 1.24 | 1.96 | 2.67 | -8.62 | 3.20 | 3.78 | 1.64 | 4.68 | 4.53 | 4.29 |
| Dividend Payout % | 22% | 35% | 91% | 81% | 51% | 37% | 0% | 31% | 26% | 61% | 26% | 26% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -20.00% | -75.00% | -100.00% | -750.00% | 138.46% | 20.00% | -50.00% | 133.33% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -55.00% | -25.00% | -650.00% | 888.46% | -118.46% | -70.00% | 183.33% | -133.33% |
Bal Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 12% |
| 3 Years: | 3% |
| TTM: | -14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 21% |
| 3 Years: | 13% |
| TTM: | -5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 14% |
| 3 Years: | -3% |
| 1 Year: | -37% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 9% |
| 3 Years: | 9% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 12:20 am
Balance Sheet
Last Updated: December 4, 2025, 1:00 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 13 | 13 | 14 | 14 | 14 | 14 | 15 | 15 | 16 | 16 | 16 | 16 |
| Reserves | 39 | 42 | 42 | 48 | 51 | 52 | 38 | 39 | 44 | 48 | 56 | 62 | 62 |
| Borrowings | 51 | 49 | 89 | 93 | 110 | 124 | 118 | 110 | 104 | 131 | 140 | 150 | 155 |
| Other Liabilities | 54 | 59 | 67 | 78 | 86 | 71 | 68 | 76 | 98 | 116 | 108 | 108 | 116 |
| Total Liabilities | 155 | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 349 |
| Fixed Assets | 55 | 52 | 56 | 60 | 71 | 70 | 71 | 69 | 67 | 76 | 80 | 87 | 92 |
| CWIP | 0 | 1 | 4 | 2 | 0 | 4 | 3 | 0 | 2 | 0 | 0 | 3 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 2 | 0 |
| Other Assets | 99 | 111 | 151 | 172 | 188 | 187 | 164 | 172 | 192 | 235 | 233 | 244 | 253 |
| Total Assets | 155 | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 349 |
Below is a detailed analysis of the balance sheet data for Bal Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Reserves, as of Sep 2025, the value is 62.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 62.00 Cr..
- For Borrowings, as of Sep 2025, the value is 155.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 150.00 Cr. (Mar 2025) to 155.00 Cr., marking an increase of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 116.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 108.00 Cr. (Mar 2025) to 116.00 Cr., marking an increase of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 349.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 336.00 Cr. (Mar 2025) to 349.00 Cr., marking an increase of 13.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 92.00 Cr.. The value appears strong and on an upward trend. It has increased from 87.00 Cr. (Mar 2025) to 92.00 Cr., marking an increase of 5.00 Cr..
- For CWIP, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 253.00 Cr.. The value appears strong and on an upward trend. It has increased from 244.00 Cr. (Mar 2025) to 253.00 Cr., marking an increase of 9.00 Cr..
- For Total Assets, as of Sep 2025, the value is 349.00 Cr.. The value appears strong and on an upward trend. It has increased from 336.00 Cr. (Mar 2025) to 349.00 Cr., marking an increase of 13.00 Cr..
However, the Borrowings (155.00 Cr.) are higher than the Reserves (62.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -33.00 | -32.00 | -74.00 | -78.00 | -93.00 | -106.00 | -113.00 | -85.00 | -80.00 | -106.00 | -109.00 | -120.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 93 | 88 | 105 | 99 | 111 | 105 | 106 | 98 | 98 | 113 | 107 | 111 |
| Inventory Days | 122 | 132 | 145 | 172 | 240 | 217 | 292 | 146 | 162 | 207 | 167 | 238 |
| Days Payable | 129 | 142 | 163 | 171 | 182 | 147 | 167 | 114 | 143 | 167 | 147 | 189 |
| Cash Conversion Cycle | 86 | 78 | 87 | 100 | 168 | 175 | 231 | 130 | 117 | 153 | 127 | 161 |
| Working Capital Days | 11 | 14 | 50 | 26 | 45 | 25 | -11 | 11 | 18 | 13 | 12 | 6 |
| ROCE % | 11% | 7% | 8% | 8% | 7% | -0% | 10% | 12% | 10% | 12% | 10% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 4.54 | 4.94 | 1.67 | 3.79 | 3.34 |
| Diluted EPS (Rs.) | 4.54 | 4.96 | 1.68 | 3.79 | 3.34 |
| Cash EPS (Rs.) | 10.68 | 11.08 | 7.49 | 9.95 | 9.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 48.63 | 43.82 | 40.60 | 39.46 | 35.99 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 48.63 | 43.82 | 40.60 | 39.46 | 35.99 |
| Revenue From Operations / Share (Rs.) | 190.37 | 214.64 | 193.89 | 189.72 | 169.02 |
| PBDIT / Share (Rs.) | 19.95 | 21.75 | 16.61 | 19.31 | 17.27 |
| PBIT / Share (Rs.) | 13.81 | 15.38 | 10.79 | 13.21 | 10.85 |
| PBT / Share (Rs.) | 3.23 | 5.72 | 3.03 | 6.20 | 2.77 |
| Net Profit / Share (Rs.) | 4.54 | 4.71 | 1.67 | 3.85 | 3.18 |
| NP After MI And SOA / Share (Rs.) | 4.53 | 4.68 | 1.64 | 3.79 | 3.20 |
| PBDIT Margin (%) | 10.47 | 10.13 | 8.56 | 10.18 | 10.21 |
| PBIT Margin (%) | 7.25 | 7.16 | 5.56 | 6.96 | 6.41 |
| PBT Margin (%) | 1.69 | 2.66 | 1.56 | 3.26 | 1.63 |
| Net Profit Margin (%) | 2.38 | 2.19 | 0.86 | 2.02 | 1.88 |
| NP After MI And SOA Margin (%) | 2.38 | 2.17 | 0.84 | 1.99 | 1.89 |
| Return on Networth / Equity (%) | 9.32 | 10.66 | 4.03 | 9.57 | 8.85 |
| Return on Capital Employeed (%) | 18.92 | 20.86 | 16.30 | 20.64 | 18.36 |
| Return On Assets (%) | 2.14 | 2.31 | 0.82 | 2.15 | 1.97 |
| Long Term Debt / Equity (X) | 0.40 | 0.52 | 0.47 | 0.46 | 0.44 |
| Total Debt / Equity (X) | 1.94 | 2.01 | 2.05 | 1.67 | 1.95 |
| Asset Turnover Ratio (%) | 0.92 | 1.07 | 1.06 | 1.12 | 0.99 |
| Current Ratio (X) | 1.07 | 1.15 | 1.09 | 1.11 | 1.08 |
| Quick Ratio (X) | 0.60 | 0.72 | 0.62 | 0.66 | 0.68 |
| Inventory Turnover Ratio (X) | 3.18 | 1.95 | 2.08 | 2.43 | 2.12 |
| Dividend Payout Ratio (NP) (%) | 26.47 | 21.22 | 60.55 | 26.41 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 11.24 | 8.98 | 13.30 | 10.11 | 0.00 |
| Earning Retention Ratio (%) | 73.53 | 78.78 | 39.45 | 73.59 | 0.00 |
| Cash Earning Retention Ratio (%) | 88.76 | 91.02 | 86.70 | 89.89 | 0.00 |
| Interest Coverage Ratio (X) | 1.88 | 2.25 | 2.14 | 2.75 | 2.14 |
| Interest Coverage Ratio (Post Tax) (X) | 1.43 | 1.49 | 1.21 | 1.55 | 1.39 |
| Enterprise Value (Cr.) | 274.72 | 270.49 | 228.31 | 252.09 | 180.34 |
| EV / Net Operating Revenue (X) | 0.90 | 0.79 | 0.75 | 0.89 | 0.71 |
| EV / EBITDA (X) | 8.65 | 7.87 | 8.76 | 8.81 | 7.05 |
| MarketCap / Net Operating Revenue (X) | 0.43 | 0.42 | 0.34 | 0.56 | 0.31 |
| Retention Ratios (%) | 73.52 | 78.77 | 39.44 | 73.58 | 0.00 |
| Price / BV (X) | 1.71 | 2.08 | 1.65 | 2.73 | 1.49 |
| Price / Net Operating Revenue (X) | 0.43 | 0.42 | 0.34 | 0.56 | 0.31 |
| EarningsYield | 0.05 | 0.05 | 0.02 | 0.03 | 0.05 |
After reviewing the key financial ratios for Bal Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 4.54. This value is below the healthy minimum of 5. It has decreased from 4.94 (Mar 24) to 4.54, marking a decrease of 0.40.
- For Diluted EPS (Rs.), as of Mar 25, the value is 4.54. This value is below the healthy minimum of 5. It has decreased from 4.96 (Mar 24) to 4.54, marking a decrease of 0.42.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.68. This value is within the healthy range. It has decreased from 11.08 (Mar 24) to 10.68, marking a decrease of 0.40.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.63. It has increased from 43.82 (Mar 24) to 48.63, marking an increase of 4.81.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.63. It has increased from 43.82 (Mar 24) to 48.63, marking an increase of 4.81.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 190.37. It has decreased from 214.64 (Mar 24) to 190.37, marking a decrease of 24.27.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 19.95. This value is within the healthy range. It has decreased from 21.75 (Mar 24) to 19.95, marking a decrease of 1.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.81. This value is within the healthy range. It has decreased from 15.38 (Mar 24) to 13.81, marking a decrease of 1.57.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.23. This value is within the healthy range. It has decreased from 5.72 (Mar 24) to 3.23, marking a decrease of 2.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 4.54. This value is within the healthy range. It has decreased from 4.71 (Mar 24) to 4.54, marking a decrease of 0.17.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 4.53. This value is within the healthy range. It has decreased from 4.68 (Mar 24) to 4.53, marking a decrease of 0.15.
- For PBDIT Margin (%), as of Mar 25, the value is 10.47. This value is within the healthy range. It has increased from 10.13 (Mar 24) to 10.47, marking an increase of 0.34.
- For PBIT Margin (%), as of Mar 25, the value is 7.25. This value is below the healthy minimum of 10. It has increased from 7.16 (Mar 24) to 7.25, marking an increase of 0.09.
- For PBT Margin (%), as of Mar 25, the value is 1.69. This value is below the healthy minimum of 10. It has decreased from 2.66 (Mar 24) to 1.69, marking a decrease of 0.97.
- For Net Profit Margin (%), as of Mar 25, the value is 2.38. This value is below the healthy minimum of 5. It has increased from 2.19 (Mar 24) to 2.38, marking an increase of 0.19.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.38. This value is below the healthy minimum of 8. It has increased from 2.17 (Mar 24) to 2.38, marking an increase of 0.21.
- For Return on Networth / Equity (%), as of Mar 25, the value is 9.32. This value is below the healthy minimum of 15. It has decreased from 10.66 (Mar 24) to 9.32, marking a decrease of 1.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is 18.92. This value is within the healthy range. It has decreased from 20.86 (Mar 24) to 18.92, marking a decrease of 1.94.
- For Return On Assets (%), as of Mar 25, the value is 2.14. This value is below the healthy minimum of 5. It has decreased from 2.31 (Mar 24) to 2.14, marking a decrease of 0.17.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.40. This value is within the healthy range. It has decreased from 0.52 (Mar 24) to 0.40, marking a decrease of 0.12.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.94. This value exceeds the healthy maximum of 1. It has decreased from 2.01 (Mar 24) to 1.94, marking a decrease of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.92. It has decreased from 1.07 (Mar 24) to 0.92, marking a decrease of 0.15.
- For Current Ratio (X), as of Mar 25, the value is 1.07. This value is below the healthy minimum of 1.5. It has decreased from 1.15 (Mar 24) to 1.07, marking a decrease of 0.08.
- For Quick Ratio (X), as of Mar 25, the value is 0.60. This value is below the healthy minimum of 1. It has decreased from 0.72 (Mar 24) to 0.60, marking a decrease of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.18. This value is below the healthy minimum of 4. It has increased from 1.95 (Mar 24) to 3.18, marking an increase of 1.23.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 26.47. This value is within the healthy range. It has increased from 21.22 (Mar 24) to 26.47, marking an increase of 5.25.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 11.24. This value is below the healthy minimum of 20. It has increased from 8.98 (Mar 24) to 11.24, marking an increase of 2.26.
- For Earning Retention Ratio (%), as of Mar 25, the value is 73.53. This value exceeds the healthy maximum of 70. It has decreased from 78.78 (Mar 24) to 73.53, marking a decrease of 5.25.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 88.76. This value exceeds the healthy maximum of 70. It has decreased from 91.02 (Mar 24) to 88.76, marking a decrease of 2.26.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.88. This value is below the healthy minimum of 3. It has decreased from 2.25 (Mar 24) to 1.88, marking a decrease of 0.37.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 3. It has decreased from 1.49 (Mar 24) to 1.43, marking a decrease of 0.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 274.72. It has increased from 270.49 (Mar 24) to 274.72, marking an increase of 4.23.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.79 (Mar 24) to 0.90, marking an increase of 0.11.
- For EV / EBITDA (X), as of Mar 25, the value is 8.65. This value is within the healthy range. It has increased from 7.87 (Mar 24) to 8.65, marking an increase of 0.78.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has increased from 0.42 (Mar 24) to 0.43, marking an increase of 0.01.
- For Retention Ratios (%), as of Mar 25, the value is 73.52. This value exceeds the healthy maximum of 70. It has decreased from 78.77 (Mar 24) to 73.52, marking a decrease of 5.25.
- For Price / BV (X), as of Mar 25, the value is 1.71. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.71, marking a decrease of 0.37.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has increased from 0.42 (Mar 24) to 0.43, marking an increase of 0.01.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bal Pharma Ltd:
- Net Profit Margin: 2.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.92% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 9.32% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.43
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.6
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 16.8 (Industry average Stock P/E: 53.49)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.94
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.38%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | # 21 & 22, Bengaluru Karnataka 560099 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Shailesh D Siroya | Managing Director |
| Mr. Himesh Virupakshaya | Executive Director |
| Mr. Ravindrakumar Kothari | Non Executive Director |
| Mr. Jatish Sheth | Independent Director |
| Ms. Nicloa Neeladri | Independent Director |
| Mr. H S Venkatesh | Independent Director |
FAQ
What is the intrinsic value of Bal Pharma Ltd?
Bal Pharma Ltd's intrinsic value (as of 01 January 2026) is ₹64.94 which is 9.93% lower the current market price of ₹72.10, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹115 Cr. market cap, FY2025-2026 high/low of ₹132/67.2, reserves of ₹62 Cr, and liabilities of ₹349 Cr.
What is the Market Cap of Bal Pharma Ltd?
The Market Cap of Bal Pharma Ltd is 115 Cr..
What is the current Stock Price of Bal Pharma Ltd as on 01 January 2026?
The current stock price of Bal Pharma Ltd as on 01 January 2026 is ₹72.1.
What is the High / Low of Bal Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bal Pharma Ltd stocks is ₹132/67.2.
What is the Stock P/E of Bal Pharma Ltd?
The Stock P/E of Bal Pharma Ltd is 16.8.
What is the Book Value of Bal Pharma Ltd?
The Book Value of Bal Pharma Ltd is 49.2.
What is the Dividend Yield of Bal Pharma Ltd?
The Dividend Yield of Bal Pharma Ltd is 1.67 %.
What is the ROCE of Bal Pharma Ltd?
The ROCE of Bal Pharma Ltd is 10.1 %.
What is the ROE of Bal Pharma Ltd?
The ROE of Bal Pharma Ltd is 9.66 %.
What is the Face Value of Bal Pharma Ltd?
The Face Value of Bal Pharma Ltd is 10.0.